Trial reportInternational journal of cancer2014
Evaluation of a multiplex panel of immune-related markers in cervical secretions: a methodologic study.
Trial report in International journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- molBV reveals immune landscape of bacterial vaginosis and predicts human papillomavirus infection natural history.Nature communications · 2022Trial
- Integrating Biomarkers into Cervical Cancer Screening-Advances in Diagnosis and Risk Prediction: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Performance of an ancillary test for cervical cancer that measures miRNAs and cytokines in serum and cervical mucus.Cancer science · 2024Article
- Predictable changes in the accuracy of human papillomavirus tests after vaccination: review with implications for performance monitoring in cervical screening.British journal of cancer · 2024Review
- Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application.Molecular cancer · 2024Review
- Blimp-1 is a prognostic indicator for progression of cervical intraepithelial neoplasia grade 2.Journal of cancer research and clinical oncology · 2022Article
- Cytokines: From Clinical Significance to Quantification.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- From Allergy to Cancer-Clinical Usefulness of Eotaxins.Cancers · 2021Review
- A prospective cohort study to evaluate immunosuppressive cytokines as predictors of viral persistence and progression to pre-malignant lesion in the cervix in women infected with HR-HPV: study protocol.BMC infectious diseases · 2018Article
- Oral sampling methods are associated with differences in immune marker concentrations.The Laryngoscope · 2018Article
- Development of podophyllotoxin‑loaded nanostructured lipid carriers for the treatment of condyloma acuminatum.Molecular medicine reports · 2018Article
- Host chemokine signature as a biomarker for the detection of pre-cancerous cervical lesions.Oncotarget · 2018Article
- Local and systemic immunomodulatory mechanisms triggered by Human Papillomavirus transformed cells: a potential role for G-CSF and neutrophils.Scientific reports · 2017Article
- Microbiome and potential targets for chemoprevention of esophageal adenocarcinoma.Seminars in oncology · 2016Review
- Effect of human papillomavirus infection on the immune system and its role in the course of cervical cancer.Oncology letters · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 1 country.
Funding
Abstract
Although persistent carcinogenic human papillomavirus (HPV) infection is necessary for cervical carcinogenesis, the cofactors involved in HPV persistence and disease progression are poorly understood. Chronic cervical inflammation may increase risk, but few studies have measured immune markers (cytokines, chemokines and soluble receptors) in cervical secretions. We evaluated the performance of 74 multiplexed, bead-based immune markers in cervical secretions from three groups of women with biopsy evaluation of cervical intraepithelial neoplasia (CIN), (i) <CIN1, HPV-negative (n = 24), (ii) <CIN1, carcinogenic HPV-positive (n = 24) and (iii) CIN2/3, carcinogenic HPV-positive (n = 48), matched on time since last period and smoking status. We considered markers with >25% detectability and >80% interclass correlation coefficients (ICCs) acceptable for epidemiologic studies. Within-batch coefficients of variation (CVs) of ≥25% indicated room for assay improvement. Secondarily, we explored associations between marker levels and CIN/HPV status adjusted for matching variables, assay batch, age and number of sexual partners. Sixty-two markers (84%) had >25% detectability and ICCs > 80%. Of those, 53 (85%) had CVs < 25%. Using these preliminary data, we found that HPV positivity was associated with increased eotaxin-1 [odds ratio (OR): 15.63, 95% confidence interval (CI): 1.26-200.00] and G-CSF (OR: 12.99, 95% CI: 1.10-142.86) among CIN-negative women. There was suggestive evidence that higher chemoattractant marker levels were associated with CIN2/3 (e.g., MIP-1delta, OR: 4.48, 95% CI: 0.87-23.04 versus <CIN1/HPV-positive). More than 70% of markers were reliably measured. This assay may be used to evaluate associations of immune-related markers with CIN and HPV status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.